Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3

Journal of the American College of Cardiology

Volumn 63, Issue 2, 2014, Pages 158-166

  Bayes Genis, Antoni ^a,b   De Antonio, Marta ^a,b   Vila, Joan ^c,d   Peñafiel, Judith ^c,d   Galán, Amparo ^a   Barallat, Jaume ^a   Zamora, Elisabet ^a,b   Urrutia, Agustin ^a,b   Lupón, Josep ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

biomarkers; heart failure; myocardial fibrosis; remodeling; survival

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; ST2 PROTEIN; UNCLASSIFIED DRUG; PROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CALIBRATION; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; RISK FACTOR; BIVARIATE ANALYSIS; CONFIDENCE INTERVAL; DEATH; FOLLOW UP; HAZARD RATIO; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; RISK ASSESSMENT;

AIC; AKAIKE INFORMATION CRITERION; BAYESIAN INFORMATION CRITERION; BIC; BIOMARKERS; CI; CONFIDENCE INTERVAL; GAL-3; GALECTIN-3; HAZARD RATIO; HEART FAILURE; HF; HIGH-SENSITIVITY SOLUBLE ST2; HR; IDI; INTEGRATED DISCRIMINATION IMPROVEMENT; INTERQUARTILE RANGE; IQR; LEFT VENTRICULAR EJECTION FRACTION; LVEF; MYOCARDIAL FIBROSIS; N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE; NET RECLASSIFICATION IMPROVEMENT; NRI; NT-PROBNP; REMODELING; ST2; SURVIVAL;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; CAUSE OF DEATH; CONFIDENCE INTERVALS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GALECTIN 3; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; SURVIVAL RATE;

EID: 84892415130     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.087     Document Type: Article

References (37)

1. E.E. Creemers, and Y.M. Pinto Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart Cardiovasc Res 89 2011 265 272
2. D. Fan, A. Takawale, J. Lee, and Z. Kassiri Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease Fibrogenesis Tissue Repair 5 2012 15
3. J.J. McMurray, and S. Stewart Epidemiology, aetiology, and prognosis of heart failure Heart 83 2000 596 602
4. J.J. McMurray, S. Adamopoulos, S.D. Anker for the ESC Committee for Practice Guidelines ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Eur Heart J 33 2012 1787 1847
5. M. Jessup, W.T. Abraham, and D.E. Casey et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 53 2009 1343 1382
6. J.A. Doust, E. Pietrzak, A. Dobson, and P. Glasziou How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ 330 2005 625
7. J.L. Januzzi Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside J Cardiovasc Transl Res 6 2013 493 500
8. E.O. Weinberg, M. Shimpo, and G.W. De Keulenaer et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction Circulation 106 2002 2961 2966
9. S. Sanada, D. Hakuno, L.J. Higgins, E.R. Schreiter, A.N.J. McEnzie, and R.T. Lee IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system J Clin Invest 117 2007 1538 1549
10. A.A. Chackerian, E.R. Oldham, E.E. Murphy, J. Schmitz, S. Pflanz, and R.A. Kastelein IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex J Immunol 179 2007 2551 2555
11. J. Dumic, S. Dabelic, and M. Flögel Galectin-3: an open-ended story Biochim Biophys Acta 1760 2006 616 635
12. A. Krzéslak, and A. Lipinska Galectin-3 as a multifunctional protein Cell Mol Biol Lett 9 2004 305 328
13. U.C. Sharma, S. Pokgarel, and T.J. van Brakel et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
14. A. Bayes-Genis, M. de Antonio, and A. Galán et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure Eur J Heart Fail 14 2012 32 38
15. R.A. De Boer, D.J. Lok, and T. Jaarsma et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
16. E. Zamora, J. Lupón, and J. Vila et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and Cockroft-Gault formulas J Am Coll Cardiol 59 2012 1709 1715
17. B. Dieplinger, J.L. Januzzi, and M. Steinmair et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Pressage ST2 assay Clin Chim Acta 409 2009 33 40
18. J.L. Januzzi, R. van Kimmenade, and J. Lainchbury et al. NT-proBNP testing for diagnosis and short-term prognosis in acute decompensated heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study Eur Heart J 27 2006 330 337
19. M.J. Pencina, R.B. D'Agostino, and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
20. C.W. Yancy, M. Jessup, B. Bozkurt for the ACCF/AHA Task Force Members 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 1495 1539
21. D.J. Lok, P. Van Der Meer, and P.W. de la Porte et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 2010 323 328
22. G.M. Felker, M. Fiuzat, and L.K. Shaw et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study Circ Heart Fail 5 2012 72 78
23. L. Gullestad, T. Ueland, and J. Kjekshus et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational trial in Heart Failure (CORONA) Am Heart J 164 2012 878 883
24. B. Ky, B. French, and K. McCloskey et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Circ Heart Fail 4 2011 180 187
25. T. Mueller, B. Dieplinger, A. Gegenhuber, W. Poelz, R. Pacher, and M. Haltmayer Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure Clin Chem 54 2008 752 756
26. K. Broch, T. Ueland, and S.H. Nymo et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology Eur J Heart Fail 8 2012 268 277
27. A. Bayes-Genis, D. Pascual-Figal, and J.L. Januzzi et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure Rev Esp Cardiol 63 2010 1171 1178
28. S.U. Rehman, T. Mueller, and J.L. Januzzi Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure J Am Coll Cardiol 52 2008 1458 1465
29. M.A. Hlatky, P. Greenland, D.K. Arnett for the American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
30. D. Giannesi Multimarker approach for heart failure management: perspectives and limitations Pharmacol Res 64 2011 11 24
31. J. Lupón, M. de Antonio, and A. Galán et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment Mayo Clin Proc 88 2013 234 243
32. D.L. Mann Mechanisms and models in heart failure: a combinatorial approach Circulation 100 1999 999 1008
33. J.E. Ho, C. Liu, and A. Lyass et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
34. R.A.P. Weir, C.J. Petrie, and A. Murphy et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction Circ Heart Fail 6 2013 492 498
35. Nativi JJ, Kremers WK, Hasin T, et al. Galectin-3, a biomarker of poor prognosis in heart failure remains unchanged after heart transplantation. Paper presented at: AHA Congress; November 4-6, 2012; Los Angeles, CA.
36. D.A. Pascual-Figal, J. Ordoñez-Llanos, P.L. Tornel for the MUSIC Investigators Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 2009 2174 2179
37. R.E. Lane, M.R. Cowie, and A.W. Chow Prediction and prevention of sudden cardiac death in heart failure Heart 91 2005 674 680